EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cloaking antibodies are prevalent in Burkholderia cepacia complex infection and their removal restores serum killing

Amy Pham, Kellynn K Y Tan, Emma L Ledger, Daniel J Smith, David W Reid, Lucy Burr, Daniel C Chambers, Timothy J Wells

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1426773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Amy Pham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, The University of Queensland, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Antibodies, Burkholderia cepacia complex, Burkholderia Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Burkholderia cepacia complex encompasses a group of gram-negative opportunistic pathogens that cause chronic lung infections in people with cystic fibrosis. Distinct from other respiratory pathogens, Burkholderia causes a unique clinical disease in a subset of patients known as ‘cepacia syndrome’, fulminant pneumonia accompanied by bacteraemia and sepsis with a mortality rate of up to 75%. Due to the bacteraemia associated with this disease, the mechanisms that allow Burkholderia to resist the bactericidal effects of serum complement-depending killing are vital. Antibodies usually promote serum killing; however, we have described ‘cloaking antibodies’, specific for lipopolysaccharides that paradoxically protect serum-sensitive bacteria from complement-mediated lysis. Cloaking antibodies that protect Pseudomonas aeruginosa have been found in 24%–41% of patients with chronic lung diseases. The presence of these antibodies is also associated with worse clinical outcomes. Here, we sought to determine the relevance of cloaking antibodies in patients with Burkholderia infection.

Methods

Twelve Burkholderia spp. were isolated from nine pwCF and characterised for susceptibility to healthy control serum. Patient serum was analysed for the titre of the cloaking antibody. The ability of the patient serum to prevent healthy control serum (HCS) killing of its cognate isolates was determined.

Results

We found that several of the Burkholderia strains were shared between patients. Ten of the 12 isolates were highly susceptible to HCS killing. Four of nine (44%) patients had cloaking antibodies that protected their cognate strain from serum killing. Depleting cloaking antibodies from patient serum restored HCS killing of Burkholderia isolates.

Discussion

Cloaking antibodies are prevalent in patients with Burkholderia pulmonary infection and protect these strains from serum killing. Removal of cloaking antibodies via plasmapheresis, as previously described for individuals with life-threatening Pseudomonas infection, may be a useful new strategy for those with serious and life-threatening Burkholderia infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntibodiesBurkholderia cepacia complexBurkholderia InfectionsHumansAntibodies, BlockingGenome, BacterialLipopolysaccharidesProspective StudiesBlood Bactericidal ActivityCystic Fibrosis

Stichwörter der Autor:innen

Burkholderia cepacia complexantibodycepacia syndromecomplementcystic fibrosisserum resistance

Substanzen

AntibodiesAntibodies, BlockingLipopolysaccharides

Autor:innen und Institutionen

  • Frazer Institute, The University of Queensland, Brisbane, QLD, Australia.
  • Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • The Adult Cystic Fibrosis Centre and Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Zitieren

APA

Pham, A., Tan, K. K. Y., Ledger, E. L., Smith, D. J., Reid, D. W., Burr, L., Chambers, D. C., & Wells, T. J. (2024). Cloaking antibodies are prevalent in Burkholderia cepacia complex infection and their removal restores serum killing. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1426773

Vancouver

Pham A, Tan KKY, Ledger EL, Smith DJ, Reid DW, Burr L, et al. Cloaking antibodies are prevalent in Burkholderia cepacia complex infection and their removal restores serum killing. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1426773

BibTeX
@article{Pham2024,
  author = {Pham, Amy and Tan, Kellynn K Y and Ledger, Emma L and Smith, Daniel J and Reid, David W and Burr, Lucy and Chambers, Daniel C and Wells, Timothy J},
  title = {Cloaking antibodies are prevalent in Burkholderia cepacia complex infection and their removal restores serum killing},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1426773}
}
Kostenlos starten →